Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5352W HIGH $3.07
Volume
1.11 M
Value Traded
2.27 M
Short % Float
11.68%
-11.17%Week
-8.4%1 Month
-6.78%3 Month
-58.51%6 Month
-94.76%5 Year
-94.76%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
214.61 M
EPS (TTM)
-0.36
P/E Ratio
-
Ent. Value
52.68 M
Total Shares
294.76 M
Float Shares
261.67 M
Insiders
11.23%
Institutions
78.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IVVD Catalyst Timeline
Dated clinical, regulatory and corporate events for Invivyd, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Invivyd, Inc.
389Total events
15Upcoming
73Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Equity OfferingCorporate
Invivyd grants inducement stock options to six newly hired non-executive employees
▲Biomarker DataVYD2311Clinical Data
LIBERTY data show no immunologic interference; VYD2311 added ~2.5x to vaccine-induced neutralizing titers
COVID-19source ↗
▲Topline ReadoutVYD2311Clinical Data
Invivyd reports positive topline results from LIBERTY Phase 3 study of VYD2311
COVID-19source ↗
▲Secondary Endpoint DataVYD2311Clinical Data
VYD2311 key secondary endpoint data from LIBERTY
COVID-19source ↗
▲Primary Endpoint MetVYD2311Clinical Data
VYD2311 met co-primary safety endpoints in LIBERTY
COVID-19source ↗
◆Oral PresentationPresentation
Investor meetings at Citi's 2026 Biopharma Back to School Conference
●R&D DayPresentation
Invivyd management to participate in Citi's 2026 Biopharma Back to School Conference (meetings only)
●FDA Feedback ReceivedVYD2311FDA Meeting
Discussions with FDA about potential paths forward
COVID-19source ↗
●Type C MeetingVYD2311FDA Meeting
Invivyd held Type C meeting with FDA regarding VYD2311 regulatory pathway
COVID-19source ↗
▲FDA Feedback ReceivedVYD2311FDA Meeting
Agreed with FDA on initial pediatric study plan for VYD2311
COVID-19source ↗
▼Drug WithdrawalPEMGARDADiscontinuedFDA Decision
FDA Notice of Termination of PEMGARDA EUA received
COVID-19 pre-exposure prophylaxissource ↗
◆Topline ReadoutVYD2311Clinical Data
Top-line data from VYD2311 program expected around end of Q3 2026
COVID-19source ↗
▼FDA Feedback ReceivedVYD2311FDA Meeting
Received twelve months' advanced notice of EUA termination for PEMGARDA
COVID-19source ↗
◆Timing GuidanceVYD2311Presentation
Plans to submit BLA towards traditional approval or Accelerated Approval
COVID-19source ↗
▲Quarterly UpdatePEMGARDADiscontinuedCorporate
Q2 2026 PEMGARDA net product revenue of $14.3 million
COVID-19source ↗
▲Enrollment CompleteVYD2311Trial
Enrollment completed in Phase 3 LIBERTY trial comparing VYD2311 vs mRNA COVID-19 vaccine
COVID-19 preventionsource ↗
▲First Patient DosedVYD2311Trial
First participants dosed in LIBERTY Phase 3 trial of VYD2311
COVID-19 preventionsource ↗
▲Enrollment CompleteVYD2311Trial
Completed enrollment in upsized DECLARATION clinical trial
COVID-19source ↗
◆Trial InitiationVYD2311Trial
Phase 2 trial in Long COVID expected to be initiated mid-2026
Long COVIDsource ↗
▲Biomarker DatapemivibartFiledClinical Data
In vitro neutralizing activity of pemivibart against SARS-CoV-2 variant BA.3.2.2 (Cicada)
COVID-19 preventionsource ↗
▲Biomarker DataVYD2311Clinical Data
In vitro neutralizing activity of VYD2311 against SARS-CoV-2 variant BA.3.2.2 (Cicada)
COVID-19 preventionsource ↗
▲DSMB ReviewVYD2311Trial
IDMC ad hoc review of unblinded VYD2311 safety data resulted in recommendation for reduction of post-dose monitoring time from two hours to thirty minutes
COVID-19 preventionsource ↗
◆Trial InitiationVYD2311Trial
LIBERTY head-to-head safety and combination study of VYD2311 vs mRNA COVID vaccine planned to begin shortly
COVID-19 preventionsource ↗
●PreprintPresentation
Preprint of adintrevimab tolerability analysis vs vaccine available on MedRxiv
COVID-19source ↗
●PreprintadintrevimabPresentation
Published preprint on safety of intramuscular anti-spike COVID-19 monoclonal antibody
COVID-19source ↗
▲Biomarker DataPEMGARDADiscontinuedClinical Data
Reported positive in vitro neutralization data for PEMGARDA against variant BA.3.2.2
COVID-19source ↗
▲Biomarker DataVYD2311Clinical Data
Reported positive in vitro neutralization data for VYD2311 against variant BA.3.2.2
COVID-19source ↗
●Oral PresentationPresentation
Sanofi presented COMPARE Phase 4 results at ESCMID 2026
COVID-19source ↗
▲Enrollment UpdateVYD2311Trial
DECLARATION study upsizing by ~500 additional subjects
COVID-19source ↗
▲FDA Feedback ReceivedVYD2311FDA Meeting
Aligned with FDA on initial Pediatric Study Plan for DRUMMER study
COVID-19source ↗
●Interim AnalysisVYD2311Trial
Pre-specified blinded sample size re-estimation analysis triggered upsizing by ~500 subjects
COVID-19 preventionsource ↗
◆Trial InitiationVYD2311Trial
Phase 2 trial of VYD2311 for Long COVID and COVID vaccine injury to commence mid-2026
Long COVID and COVID vaccine injurysource ↗
◆Topline ReadoutVYD2311Clinical Data
Top-line data from DECLARATION expected mid-2026
COVID-19 preventionsource ↗
◆Enrollment UpdateVYD2311Trial
Potential trial up-sizing decision for DECLARATION
COVID-19 preventionsource ↗
▲DSMB ReviewVYD2311Trial
IDMC completed prespecified review of unblinded safety data at early timepoint; pregnant/breastfeeding women eligible, contraception not required, safety visits reduced
COVID-19 preventionsource ↗
Past FDA Catalysts and PDUFA Decisions
How IVVD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | VYD2311 | BLA Submission | BLA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$177M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
0.7x
rNPV / MCap
Top 29%
Micro Cap(rank 192 of 658)
Percentile Rank
Invivyd, Inc. carries a moderate pipeline score (44/100), with $946M risk-adjusted pipeline value, led by VYD2311 in COVID-19 (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VYD2311 Monoclonal antibodyNCT06523153 | COVID-19 | Phase 3 | ACTIVE NOT_RECRUITING | 2,020 | May 1, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every IVVD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VYD2311 Fast Track | COVID-19 | Phase 3 | 2026-09-29 | VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccineRead More | Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lee Timothy EdwardOfficer (Chief Commercial Officer) | Sell | -18,425 178,937 held | $0.84 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IVVD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.6 % (-25 %) | 24.57 M | 28.16 M | 44.25% ( 8.64 M) |
IVVD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IVVD ranks across every disease it competes in
Competitive Position is a premium feature
See how IVVD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIVVD News
IVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. announced the grant of stock options to six newly hired non-executive employees as an inducement for their employment. The options, totaling 157,500 shares, have a per share exercise price of $0.8165 and will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's 2026 Inducement Plan.
Read more →IVVD▼ -10.5%on this news
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
Invivyd announced positive topline results from the LIBERTY Phase 3 study, showing that VYD2311, its investigational monoclonal antibody, has superior safety and tolerability compared to an mRNA-based COVID-19 vaccine. The study demonstrated that VYD2311 can enhance vaccine-induced neutralizing titers without interference. Invivyd plans to submit a Biologics License Application to the FDA based on these results.
Read more →IVVDInvivyd to Participate in Upcoming September Investor Conferences
Invivyd, Inc. has announced its participation in three upcoming investor conferences in September 2026. CEO Marc W. Elia and management will engage with investors at the Citi Biopharma Conference, Cantor Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. Live webcasts of the events will be available on the company's investor website.
Read more →IVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. announced the grant of stock options to six new non-executive employees as an inducement for their employment. The options total 255,000 shares and are priced at $0.8799 each, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's 2026 Inducement Plan.
Read more →IVVD▼ -7.9%on this news
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
Invivyd has appointed Marc Elia as CEO, who previously served as Chairman. The company is nearing completion of its VYD2311 studies, with updates anticipated shortly. VYD2311 aims to provide new options for COVID-19 prevention and treatment, leveraging advanced monoclonal antibody technology. The company is also preparing for potential FDA submissions based on study outcomes.
Read more →IVVD▲ +5.1%on this news· ran to +40% by day 3
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Invivyd reported a 21% increase in net product revenue for PEMGARDA, reaching $14.3 million in Q2 2026. The company completed enrollment in its DECLARATION and LIBERTY clinical trials, with top-line data expected later this year. Despite a strong cash position of $160.1 million, Invivyd faces challenges, including the impending termination of PEMGARDA's emergency use authorization.
Read more →IVVD▼ -6.7%on this news
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
Invivyd has received a Notice of Termination for the Emergency Use Authorization (EUA) of PEMGARDA, effective June 29, 2027. The company is in discussions with the FDA regarding next steps to secure permanent approval for this monoclonal antibody, which has shown strong efficacy in clinical trials. Despite the termination notice, Invivyd remains committed to providing protection for vulnerable populations against COVID-19.
Read more →IVVDInvivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
Invivyd has completed participant enrollment in its Phase 3 LIBERTY trial, which compares the monoclonal antibody VYD2311 with an mRNA COVID-19 vaccine. The trial aims to assess safety, tolerability, and immune response. Initial results are anticipated in Q3 2026, potentially alongside data from the DECLARATION trial, as Invivyd seeks to establish VYD2311 as a viable alternative for COVID-19 prevention.
Read more →IVVDInvivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
Invivyd has commenced dosing participants in its LIBERTY Phase 3 clinical trial, which aims to evaluate the safety and tolerability of its monoclonal antibody VYD2311 compared to an mRNA COVID-19 vaccine. The trial will also explore the effects of co-administering VYD2311 with the vaccine. Topline data is expected in Q3 2026, alongside results from the DECLARATION trial.
Read more →IVVD▲ +7%on this newsshared move
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
Invivyd has completed enrollment in its DECLARATION trial, a Phase 3 study evaluating VYD2311, an investigational monoclonal antibody for preventing symptomatic COVID-19. The trial includes both single and monthly dosing arms, with top-line results expected in late Q3 2026. The study aims to provide data on the safety and efficacy of VYD2311 in a broad population.
Read more →IVVDInvivyd to Participate in Upcoming Investor Events
Invivyd, Inc. has announced its participation in several upcoming investor events in June 2026, including the Jefferies Global Healthcare Conference and H.C. Wainwright's 'HCW @ Home' series. The management team will also host investor meetings during these events. The company focuses on developing innovative antibodies for viral infectious diseases, having received FDA emergency use authorization for one of its monoclonal antibodies.
Read more →IVVD▼ -21.1%on this news
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
Invivyd, Inc. reported its Q1 2026 financial results, showcasing a 22% increase in net product revenue from PEMGARDA, amounting to $13.7 million. The company confirmed the effectiveness of its monoclonal antibody VYD2311 against the SARS-CoV-2 variant BA.3.2.2. Despite a significant increase in operating expenses linked to clinical trials, Invivyd maintains a robust cash position of $184.2 million.
Read more →IVVDInvivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
Invivyd has released a preprint manuscript evaluating the tolerability of its investigational monoclonal antibody adintrevimab in comparison to COVID-19 vaccines. The study indicates that adintrevimab has minimal side effects, suggesting a significant difference in tolerability compared to vaccines. The upcoming LIBERTY trial will further investigate the safety of VYD2311 against mRNA vaccines.
Read more →IVVDInvivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
Invivyd, Inc. has announced a conference call scheduled for May 14, 2026, to discuss its first quarter financial results and provide a corporate update. The call will begin at 8:30 a.m. ET, with a registration link available for interested parties. The company is known for its focus on developing antibodies for viral infectious diseases.
Read more →IVVDInvivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
Invivyd's Chairman, Marc Elia, will speak at the POLITICO Health Care Summit on April 21, discussing the role of monoclonal antibodies in viral disease prevention. The event aims to connect policymakers and health experts to explore the future of American health care. Elia emphasizes the importance of advanced monoclonal antibodies beyond vaccines for improving health outcomes.
Read more →About Invivyd, Inc.
Headquarters209 CHURCH STREET, NEW HAVEN, CT, 06510
BIOPHARMAWATCH ELITE PLUS
Trade the next IVVD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime